Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PLAT | P00750 | 8/20 | 0.34 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.33 |
| ▸ | PKM | P14618 | 1/20 | 0.33 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.32 |
| ▸ | HPGD | P15428 | 2/20 | 0.32 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.32 |
| ▸ | MEN1 | O00255 | 1/20 | 0.32 |
| ▸ | POLB | P06746 | 1/20 | 0.32 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.32 |
| ▸ | NPC1 | O15118 | 1/20 | 0.31 |
| ▸ | RAB9A | P51151 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL15308503 | 0.79 | ALDH1A1 (0.34) | KDM4EALDH1A1HPGDSMN1; SMN2MEN1 | |
| SCHEMBL5787815 | 0.75 | NPY1R (0.35) | PLATKDM4EALDH1A1HPGDSMN1; SMN2 | |
| SCHEMBL16629031 | 0.73 | ALDH1A1 (0.33) | KDM4EALDH1A1HPGDSMN1; SMN2MEN1 | |
| SCHEMBL20971707 | 0.71 | ALDH1A1 (0.31) | KDM4EALDH1A1HPGDSMN1; SMN2MEN1 | |
| SCHEMBL19863964 | 0.71 | ALDH1A1 (0.31) | KDM4EALDH1A1HPGDSMN1; SMN2MEN1 | |
| SCHEMBL16946611 | 0.70 | PLAT (0.56) | PLATKDM4EALDH1A1SMN1; SMN2KMT2A | |
| SCHEMBL15308601 | 0.70 | PLAT (0.47) | PLATKDM4EALDH1A1HPGDSMN1; SMN2 | |
| SCHEMBL16077836 | 0.70 | PLAT (0.47) | PLATKDM4EALDH1A1HPGDPOLB | |
| SCHEMBL31624208 | 0.67 | PLAT (0.49) | PLATKDM4EALDH1A1HPGDSMN1; SMN2 | |
| SCHEMBL16535098 | 0.65 | EGLN2 (0.40) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-0923582-B1 | SUBSTITUTED 6,5-HETERO-BICYCLIC DERIVATIVES | PFIZER (US) | 2006-09-20 | — | — | EP | disclosed |
| US-6900217-B2 | Substituted 6,5-hetero-bicyclic derivatives | PFIZER INC (US) | 2005-05-31 | — | — | US | disclosed |
| US-20050009823-A1 | Substituted 6,5-hetero-bicyclic derivatives | PFIZER INC | 2005-01-13 | — | — | US | disclosed |
| US-20020151713-A1 | Substituted 6,5-hetero-bicyclic derivatives | PFIZER INC. | 2002-10-17 | — | — | US | disclosed |
| US-20010007867-A1 | SUBSTITUTED 6,5-HETERO-BICYCLIC DERIVATIVES | CHEN YUHPYNG L (US) | 2001-07-12 | — | — | US | disclosed |
| EP-0923582-A1 | SUBSTITUTED 6,5-HETERO-BICYCLIC DERIVATIVES | PFIZER INC. (US) | 1999-06-23 | — | — | EP | disclosed |
| WO-1998008847-A1 | SUBSTITUTED 6,5-HETERO-BICYCLIC DERIVATIVES | PFIZER INC. (US) | 1998-03-05 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050009823-A1 | Substituted 6,5-hetero-bicyclic derivatives | CYP2D6, CYP2B6, ABCG2 | PLAT 3310/4885KDM4E 895/4885PKM 1474/4885 |
| US-20020151713-A1 | Substituted 6,5-hetero-bicyclic derivatives | CYP2D6, CYP2B6, CYP3A5 | PLAT 3796/4885KDM4E 541/4885PKM 1379/4885 |
| US-20010007867-A1 | SUBSTITUTED 6,5-HETERO-BICYCLIC DERIVATIVES | CYP2D6, CYP2B6, CYP3A5 | PLAT 4237/4885KDM4E 836/4885PKM 1679/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.